Please login to the form below

Not currently logged in
Email:
Password:

HIV drug approved

Full marketing authorisation has been granted to Boehringer for its HIV protease inhibitor, Aptivus (tipranavir)
Full marketing authorisation has been granted to Boehringer for its HIV protease inhibitor (PI), Aptivus (tipranavir).

The European Commission has approved the drug, which has been developed to suppress HIV in treatment-experienced patients who have acquired a resistance to other PIs.

"This full approval demonstrates the confidence that the authorities have in the benefit of Aptivus for patients with a resistant virus," said Dr Andrea Barner, member of the board of Boehringer Ingelheim and responsible for research, development and medicine.

HIV has progressed to a point where a growing number of people across Europe are carrying strains of the disease which are resistant to various therapeutic options. Boehringer says that a study in Spain showed that 43 per cent of patients treated for more than eight years have more than five protease resistance mutations.

Aptivus is the first non-peptidic PI treatment and showed good anti-viral activity during trials. Over 1,400 patients were involved in two large studies, Resist I and II, located at different centres. It was the largest evaluation conducted to date of treatment-experienced patients, and proved the efficacy and safety of the medicine, which has been shown to combat drug-resistant strains of HIV.

7th May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....

Infographics